Skip to contentX
Xenon Pharmaceuticals Inc.
X
XENEXenon Pharmaceuticals Inc. Q3 2022 · 10-Q
Revenue$132.00K$132.00K−98.4% vs Q3 2021 Net Income-$37.15M-$37.15MN/M vs Q3 2021 EPS Diluted-$0.57-$0.57N/M vs Q3 2021 Operating Income-$38,128,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenon Pharmaceuticals Inc. · CIK 1582313 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$30,788,000N/M Margins · derivedOperating margin-28884.8%−28692.8 pt vs Q3 2021
Net margin-28143.9%−27953.8 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 8, 2022 · 39 d after period end